Kelley Wilson
Psychiatry · Tampa, FLNPI 1932398757
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 38.3% of the total. Reporting peaked in 2019 at $3,773 and has fallen 81.0% since, to $717 in 2025.
Across 137 payments — averaging $56.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Neuronetics, Inc.$1K
- Eli Lilly$662
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$429
- AbbVie$308
- Alkermes, Inc.$294
- plus $2K from 20 others
Across 1,104 payments — averaging $10,018 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.3M
- Janssen Research & Development, LLC$2.2M
- Incyte Corporation$1.6M
- Roche Diagnostics Operations, Inc.$966K
- E.r. Squibb & Sons, L.L.C.$884K
- Sumitomo Pharma America, Inc.$761K
- plus $2.3M from 20 others
What the payments were for
- Speaking & faculty fees$2,60034%
- Travel & lodging$1,19916%
- Food & beverage$3,86950%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $2,958 |
| Neuronetics, Inc. | 8 | $1,048 |
| Eli Lilly | 2 | $662 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $429 |
| AbbVie(2 entities) | 9 | $308 |
| Alkermes, Inc. | 10 | $294 |
| Neos Therapeutics, LP | 10 | $277 |
| Corium, LLC | 8 | $261 |
| Otsuka America Pharmaceutical, Inc. | 11 | $221 |
| Noven Therapeutics, LLC | 11 | $209 |
| Regeneron Healthcare Solutions, Inc. | 6 | $167 |
| Idorsia Pharmaceuticals US Inc | 2 | $148 |
| Neurocrine Biosciences, Inc. | 6 | $130 |
| Tris Pharma Inc | 5 | $87 |
| Almatica Pharma LLC | 4 | $79 |
| Galderma Laboratories, L.p. | 1 | $74 |
| Sanofi | 3 | $66 |
| Merck | 1 | $56 |
| Lundbeck LLC | 3 | $51 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Dermira, Inc. | 2 | $30 |
| Lilly USA, LLC | 1 | $29 |
| Bausch Health US, LLC | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Journey Medical Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$2,725
- NEUROSTAR TMS THERAPY$697
- Adzenys XR-ODT$141
- QUVIVIQ$125
- CAPLYTA$125
- Azstarys$122
- VRAYLAR$118
How this compares
$7,718 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Tampa
- David SheehanTampa$631K
- Jamie FernandezTampa$418K
- Hardeep SinghTampa$374K
- Kenneth PagesTampa$274K
- Chetan GandhyTampa$94K
- Deborah Knudson GonzalezTampa$81K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.